Back to top

Image: Bigstock

Is a GlaxoSmithKline (GSK) Good Value Investor Stock Now?

Read MoreHide Full Article

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put GlaxoSmithKline plc (GSK - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, GlaxoSmithKline has a trailing twelve months PE ratio of 12.15, as you can see in the chart below:


 
This level actually compares favorably with the market at large, as the PE for the S&P 500 stands at about 25.82. If we focus on the long-term PE trend, GlaxoSmithKline’s current PE level puts it below its midpoint over the past five years. Moreover, the current level is fairly below the highs for this stock, suggesting it might be a good entry point.


 
However, the stock’s PE also compares unfavorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 25.07. At the very least, this indicates that the stock is slightly undervalued right now, compared to its peers.


 
We should also point out that GlaxoSmithKline has a forward PE ratio (price relative to this year’s earnings) of just 12.16, so it is fair to expect an increase in the company’s share price in the near future.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, GlaxoSmithKline has a P/S ratio of about 2.08. This is substantially lower than the S&P 500 average, which comes in at 4.53 right now. Also, as we can see in the chart below, this is somewhat below the highs for this stock in particular over the past few years.

Broad Value Outlook

In aggregate, GlaxoSmithKline currently has a Value Score of A, putting it into the top 20% of all stocks we cover from this look. This makes GlaxoSmithKline a solid choice for value investors, and some of its other key metrics make this pretty clear too.

For example, its P/CF ratio (another great indicator of value) comes in at 8.44, which is better than the industry average of 10.73. Clearly, GSK is a solid choice on the value front from multiple angles.

What About the Stock Overall?

Though GlaxoSmithKline might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of D and Momentum Score of A. This gives GlaxoSmithKline a Zacks VGM score — or its overarching fundamental grade — of B. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been mixed, at the best. The current quarter has seen no upward revision in the past sixty days compared to one downward revision, while the current year estimate has seen one upward revision compared to one downward revision in the same time period.

This has had a noticeable impact on the consensus estimate, as the current quarter consensus estimate declined 4.3% in the past two months, whereas the current year estimate remained unchanged in the past two months. You can see the consensus estimate trend and recent price action for the stock in the chart below:

GlaxoSmithKline plc Price and Consensus

Owing to mixed estimate trends, the stock has a Zacks Rank #3 (Hold), which is why we are looking for in-line performance from the company in the near term.

Bottom Line

GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past two years, the sector has clearly underperformed the market at large, as you can see below:


 
So, value investors might want to wait for estimates, analyst sentiment and broader factors to turn around in this name first, but once that happens, this stock could be a compelling pick.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>


More In-Depth Research from Zacks


Normally $25 each - click below to receive one report FREE:


GlaxoSmithKline plc (GSK) - free report >>

Published in